Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses hormone replacement therapy for women with premature ovarian insufficiency, strongly recommending it for symptom relief and bone protection, but notes a lack of evidence on optimal types and doses.

This study suggests that hydroxypinacolone retinoate (HPR) may be an effective alternative to tretinoin for anti-aging skin treatments, offering similar collagen production benefits without increased skin irritation.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.

This study developed a method using UHPLC-MS/MS and MSPE to detect trace amounts of sex hormones in cosmetics, finding progestins and estrogens in some products, and performed a preliminary safety evaluation for residual progesterone in hair loss prevention cosmetics.

This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.

This review concludes that antiandrogens with ovarian suppression may significantly improve hirsutism and androgenetic alopecia in women with PCOS, but treatment needs to continue unless the underlying PCOS cause is addressed.

This study found that a low estrogen-containing oral contraceptive normalized hormone levels and improved symptoms in women with polycystic ovary disease, with minimal side effects reported.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.

This retrospective study found that cyproterone acetate, both alone and with estrogens, was safe, well tolerated, and induced modest feminizing effects in late-pubertal transgender female adolescents.

This study found that high doses of progesterone significantly inhibited neuroblastoma growth in both in vitro and mouse models, while showing selective toxicity and minimal harm to healthy cells.

A new antiandrogen compound was made and its detailed three-dimensional shape was described.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This study found that women with polycystic ovary syndrome have more pronounced metabolic alterations and higher androgen levels compared to women with eumenorrheic hyperandrogenism, suggesting EuHyperA may be a milder form of PCOS.

This review found that women with idiopathic hirsutism may have increased 5α-reductase activity, as indicated by elevated levels of a dihydrotestosterone-reduced metabolite, but more research is needed to confirm its clinical relevance as a biomarker.

This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.

This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.

This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

This paper reviews the diagnostic criteria, associated morbidities, and possible evolutionary advantages of polycystic ovary syndrome, but does not report any new findings.

This article reviews the clinical features, diagnostic criteria, and possible genetic and environmental influences of polycystic ovary syndrome but provides no new research findings.

This review analyzes the reported prevalence of polycystic ovary syndrome (PCOS) based on different diagnostic criteria but does not provide new clinical results.

This study observed that among a cohort of reproductive-aged women in the U.S., the prevalence of PCOS was about 4.0%, with no significant racial differences between White and Black women.

This study found that the prevalence of polycystic ovary syndrome was 6.5% in a minimally biased sample of Caucasian women from Spain.

This paper reviews the diagnostic criteria, etiological factors, and treatment approaches for PCOS, highlighting the importance of considering metabolic issues such as insulin resistance and obesity, but reports no new findings.

This hypothesis paper suggests that PCOS may result from genetically determined ovarian hypersecretion of androgens, influencing hormone regulation and insulin resistance, with obesity further affecting its severity; no new clinical results are reported.

This study estimates the total cost of evaluating and treating polycystic ovary syndrome in reproductive-aged women in the United States to be $4.36 billion, suggesting more liberal screening could be beneficial.

This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.

This study found that the prevalence of PCOS in a population of unselected U.S. women was 4.0%, with no significant racial differences between White and Black women.